A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Study sponsor: Karyopharm Therapeutics Inc · KPTI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-06-24Actual
Enrollment · participants13Actual
Source updated2023-11-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.